Corticosteroid Therapy in IgA Nephropathy
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
The benefits and risks of steroids for the treatment of IgA nephropathy remain uncertain. We systematically searched MEDLINE, EMBASE, and the Cochrane Library for randomized, controlled trials of corticosteroid therapy for IgA nephropathy published between 1966 and March 2011. We identified nine relevant trials that included 536 patients who had urinary protein excretion >1 g/d and normal renal function. Forty-six (8.6%) of these patients developed a kidney failure event, defined as doubling of the serum creatinine/halving of the GFR or ESRD. Overall, steroid therapy was associated with a lower risk for kidney failure (relative risk, 0.32 [95% confidence interval [CI], 0.15-0.67]; P=0.002) and a reduction in proteinuria (weighted mean difference, -0.46 g/d [95% CI, -0.63 to -0.29 g/d]), with no evidence of heterogeneity in these outcomes. Subgroup analysis suggested that the dose modifies the effect of steroids for renal protection (P for heterogeneity=0.030): Relatively high-dose and short-term therapy (prednisone >30 mg/d or high-dose pulse intravenous methylprednisolone with duration ≤1 year) produced significant renal protection, whereas low-dose, long-term steroid use did not. Steroid therapy was associated with a 55% higher risk for adverse events. The quality of included studies was low, however, limiting the generalizability of the results. In conclusion, steroids appear to provide renal protection in patients with IgA nephropathy but increase the risk for adverse events. Reliably defining the efficacy and safety of steroids in IgA nephropathy requires a high-quality trial with a large sample size.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A meta-analysis published in 2012 suggested that there were bene fi ts resulting from the use of corticosteroid therapy, but it was noted that trials included in the meta-analysis were small and of poor quality, with adverse outcomes not fully reported. 27”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [27]
In the citing paper
“A meta-analysis published in 2012 suggested that there were bene fi ts resulting from the use of corticosteroid therapy, but it was noted that trials included in the meta-analysis were small and of poor quality, with adverse outcomes not fully reported. 27”
From A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy (2021) · cites this paper as [27]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Commonest Glomerulonephritis in the World: IgA Nephropathy
(1987) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068143 · Cited by 870
Bias in meta-analysis detected by a simple, graphical
Stuck, A. E., Rubenstein, L. Z., Wieland, D., Vandenbroucke, J. P., Irwig, L., Macaskill, P., Berry, G., Glasziou, P., Seagroatt, V., Stratton, I., et al. (1998) · BMJ · doi:10.1136/bmj.316.7129.469 · Cited by 699
Donadio, J. V., & Grande, J. P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020109 · Cited by 661
Remission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
Corticosteroids in IgA nephropathy: a randomised controlled trial
Pozzi, C., Bolasco, P., Fogazzi, G., Andrulli, S., Altieri, P., Ponticelli, C., & Locatelli, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03563-6 · Cited by 532
Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors
D’Amico, G. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.8966 · Cited by 499
Thompson, S. G., & Pocock, S. J. (1991) · The Lancet · doi:10.1016/0140-6736(91)91975-z · Cited by 487
Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial
Pozzi, C., Andrulli, S., Del Vecchio, L., Melis, P., Fogazzi, G. B., Altieri, P., Ponticelli, C., & Locatelli, F. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000103869.08096.4f · Cited by 484
Suzuki, H., Fan, R., Zhang, Z., Brown, R., Hall, S., Julian, B. A., Chatham, W. W., Suzuki, Y., Wyatt, R. J., Moldoveanu, Z., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38468 · Cited by 450
Predicting the Risk for Dialysis or Death in IgA Nephropathy
Berthoux, F., Mohey, H., Laurent, B., Mariat, C., Afiani, A., & Thibaudin, L. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010040355 · Cited by 361
Manno, C., Torres, D. D., Rossini, M., Pesce, F., & Schena, F. P. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp356 · Cited by 311
IgA nephropathy, the most common glomerulonephritis worldwide
Julian, B. A., Waldo, F. B., Rifai, A., & Mestecky, J. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90019-8 · Cited by 242
Lv, J., Zhang, H., Chen, Y., Li, G., Jiang, L., Singh, A. K., & Wang, H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.029 · Cited by 238
Self-citationEpidemiology: Study Design and Data Analysis (2nd ed.)
Davies, S. (2006) · Quarterly Publications of the American Statistical Association · Cited by 172
Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial.
Lai, K. N., Lai, F. M., HO, C. P., & Chan, K. W. (1986) · PubMed · Cited by 167
Katafuchi, R., Ikeda, K., Mizumasa, T., Tanaka, H., Ando, T., Yanase, T., Masutani, K., Kubo, M., & Fujimi, S. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00194-x · Cited by 142
Hogg, R. J., Lee, J. Y., Nardelli, N., Julian, B. A., Cattran, D., Waldo, B., Wyatt, R. J., Jennette, J. C., Sibley, R. K., Hyland, Κ., et al. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01020905 · Cited by 133
Immunosuppressive agents for treating IgA nephropathy
Vecchio, M., Bonerba, B., Palmer, S. C., Craig, J. C., Ruospo, M., Samuels, J., Molony, D. A., Schena, F. P., & Strippoli, G. F. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003965.pub2 · Cited by 119
Shoji, T., Nakanishi, I., Suzuki, A., Hayashi, T., Togawa, M., Okada, N., Imai, E., Hori, M., & Tsubakihara, Y. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70326-x · Cited by 107
LV, J., ZHANG, H., ZHOU, Y., LI, G., ZOU, W., & WANG, H. (2008) · Nephrology · doi:10.1111/j.1440-1797.2007.00898.x · Cited by 100
Self-citationEitner, F., Ackermann, D., Hilgers, R.-D., & Floege1, J. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.3.284 · Cited by 74
Non-immunosuppressive treatment for IgA nephropathy
Reid, S., Cawthon, P. M., Craig, J. C., Samuels, J. A., Molony, D. A., & Strippoli, G. F. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003962.pub2 · Cited by 72
Julian, B. A., & Barker, C. (1993) · PubMed · Cited by 51
Cheng, J., Zhang, X., Zhang, W., He, Q., Tao, X., & Chen, J. (2009) · American Journal of Nephrology · doi:10.1159/000226129 · Cited by 50
Alternate-Day Prednisone Therapy in IgA Nephropathy
Julian, B. A., & Barker, C. V. (2015) · Contributions to nephrology · doi:10.1159/000422413 · Cited by 47
Zhou, Y.-H., Tang, L.-G., Guo, S.-L., Jin, Z.-C., Wu, M.-J., Zang, J., Xu, J., Wu, C.-F., Qin, Y.-Y., Cai, Q., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018788 · Cited by 30
Koike, M., Takei, T., Uchida, K., Honda, K., Moriyama, T., Horita, S., Ogawa, T., Yoshida, T., Tsuchiya, K., & Nitta, K. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0036-7 · Cited by 28
Analyzing antibody activity in IgA nephropathy
Glassock, R. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39189 · Cited by 28
Cited by
Rodrigues, J. C., Haas, M., & Reich, H. N. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07420716 · Cited by 555
Lv, J., Zhang, H., Wong, M. G., Jardine, M. J., Hladunewich, M., Jha, V., Monaghan, H., Zhao, M., Barbour, S., Reich, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.9362 · Cited by 540
Self-citationLai, K. N., Tang, S. C. W., Schena, F. P., Novak, J., Tomino, Y., Fogo, A. B., & Glassock, R. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.1 · Cited by 508
“A metaanalysis of nine RCTs (including 536 patients with urinary protein excretion of >1 g per day and normal renal function) suggested that highdose, shortterm corticosteroid therapy produced significant renal protection, whereas lowdose, longterm corticosteroid use did not 93 .”
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
“A meta-analysis published in 2012 suggested that there were benefits resulting from the use of corticosteroid therapy, but it was noted that trials included in the meta-analysis were small and of poor quality, with adverse outcomes not fully reported.(26) Since then, larger clinical trials have addressed the role of s…”
ResultFellström, B. C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J. W., Floege, J., Hetzel, G., Jardine, A. G., Locatelli, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30550-0 · Cited by 414
Metadata
- Authors
- Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H.
- Affiliations
- Peking University (CN)
- The University of Sydney (AU)
- The University of Queensland (AU)
- University of British Columbia (CA)
- Corresponding author
- Lv, Jicheng
- Xu, Damin
- Ma, Xinxin
- Zhang, Hong
- Wang, Haiyan
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2012-06
- Volume
- 23
- Issue
- 6
- Pages
- 1108-1116
- ISSN
- 1046-6673 (ISSN-L)
- PMC
- PMC3358763
- OpenAlex
- W2107238505
- Cited by
- 190
- References
- 33
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 12 · 2021: 13 · 2020: 13 · 2019: 13 · 2018: 16 · 2017: 24 · 2016: 22 · 2015: 16 · 2014: 13 · 2013: 13 · 2012: 2
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- IgA nephropathy, corticosteroid therapy, prednisone, methylprednisolone pulse therapy, proteinuria, renal failure, renal protection, adverse events
- MeSH terms
- Administration, Oral, Adrenal Cortex Hormones, China, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glomerulonephritis, IGA, Humans, Infusions, Intravenous, Kidney Failure, Chronic, Kidney Function Tests, Male, Methylprednisolone, Prednisone, Prognosis, Severity of Illness Index, Survival Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Disease-Free Survival, Pulse Therapy, Drug
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.